in zebra, i like kweb. >> i'm going to wish karen's dad a happy new year, why not? lockheed martin. defense spending is now 60% of the budget. lmt. >> thank you for watching "fast money." 00e you back here tomorrow at 5:. meantime, >> reporter: my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a more -- i promise to help you find it. mad money starts now. hey, i'm cramer. welcome to very special san francisco edition of mad money. welcome to cramer. i'm just trying to make you money. my job is to entertain and educate and teach. so called me at 1-800-743-cnbc or tweet me at @jimcramer. holy cow don't give up on apple. stop selling them video, please. get back into microsoft.

and don't forget meta platforms. you ignored these stocks, you're having a risk. that's how you end up with a day where the dow is down 17 points. as the -- and attack lid nasa stands an outstanding 2.2%. yet today we celebrated tech. with a market turn on the -- especially if you view it in personal pews. of the stocks that sold and instead people bought the banks, other retailers, and most importantly the health care stocks. one reason i found myself at jpmorgan central health care converse, albeit the industry's most important event, year after year. last week i told you that the first time they don't tell you about where things are headed. as always, when you decided to jump all things tech, don't forget to send me an invitation to your funeral. right now, there is a rival commerce about -- maybe it's a 564 miles, in las vegas. ces, but consumer electronics show's. where in videos unveiling

generative a.i. chips for personal computers. they're a.i. to millions of regular people, not just the hottest in the enterprises. and it could be the first major reason to buy a new pc in ages. i think these chips will spur new sales for everything connected to computers, from micron and dell, two h, b microsoft. hey, maybe even best buy. as -- we have prevents since a video, what i called the da vinci, set up the introduction, gervais is the ceo most significant platform transition in computing history. and will transform every industry. how big? how about 100 million pc and workstations? no wonder the stop that seemingly stalled when of $31 and 6% even after it was the most -- more than tripling on exploding chip sales for generative a.i.. well it can top the envy to news. apple stopped broke its four-day skit and jumped for a change, based on positive pushes launched by every, quite

a, aside jpmorgan, and morgan stanley. and -- artificial intelligence. plus, apple gave you a launch date for the vision probe, revolutionary headset. it promises remarkable resolution and dynamite toggling but the click of your thumb and index finger. i bet app aficionados clean maple eat up when it start selling on february 2nd. sure, we had a reports today from -- 30% in china, in the first week of 2024. and it's a worsening trend. never mind that iphone -- there was an iphone that flew out of a whole, in a bowling play friday and survive to 16,000 footfall and worked perfectly. i, know it's not enough to offset the huge market that is china. the numbers may be too high for the cupertino collapses, but a, i the vision, probe in strong service revenue makes people rethink selling stock. it's the person from as high as apple was on friday's close. oh, did anyone mention apple stock was up 40% last year?

i recall that hardly a disappointment. you bet against this one at your own peril. yes, this is the kind of news flow that always gets people excited and gets the nasdaq really rolling. you simply have to own some of the magnificent -- after last week's big down. you might ask, what the heck am i doing out here in this conference? this health care conference in self francisco? am i in the wrong confab? hardly. people should recognize that the disparity and die between the health care countries that are saving lives and tackling concert, heart disease, and yes, obesity and diabetes, and the companies that help them make a better computer, this is just a great. right, now only eli the way that -- for obesity has gotten the deserved attention. these diseases are hard derailing, they can lead to cardiovascular illness and death. so you can't really put a price on extending your life. and what elie louis stock is a 5.5 million dollar company, still away from the trillion dollar status.

maybe that's the opportunity. maybe the opportunity's been with what will greens. the former drug store fell -- almost in half last week. but the stocks down, even -- it still yields 4%. i know, it still some time to get a higher yield. but you have to take what you can. get dribble learn later when we speak to the ceo. and -- with the ceo about tackling the toughest of the toughest, schizophrenia. a new free or charge which is the product that is merging with karen therapeutics for 14 billion dollars in cash. if it, works the merch could help conquer all summer psychosis, bipolar disorder to. the dealer of the takeovers breed that bristle building on, they want to build their drugs on cardiovascular disease before their drug starts losing protection. should the -- the fraction of what we pay for techno launch -- if you're trying to conquer diabetes and obesity, isn't

that market moving? people have been using that for years. and -- right now, with the exception of eli louis with the revolutionary gop weight loss drug, they are on a bomb market and government reimbursement use than on actual prospect. i'm here to find out just how wrong that is, and believe me, it is very wrong. don't forget that what we care about is percentage case, not incremental gains. and i think you find better percentage gains in health care especially if you don't fight with the next over -- in the farmers space, most willing -- for the revolutionary drugs. of course, this remarkable intersection between tech and medicine. [inaudible] the ceo of medtronic's both his companies alliance with -- can catch everything. right, now a typical colonoscopy can miss out more than 15% of can stroll possibilities. and -- new drug discovery. in the, and stuff like

microsoft and video, which are bringing a.i. to the pc, and stocks like apple which is in graining artificial intelligence but the cell phone, are going to offer amazing investment opportunities. but the bottom line, i, here i think a well-rounded person's portfolio has health care to. and that's the best reason to buy shares in the companies that you will hear about today and tomorrow. coming to you from beautiful san francisco, at the annual jpmorgan health care conference extravaganza, let's take calls. let me start with george in michigan. george -- hague, jim, how you doing, guy? >> reporter: i'm doing well, how about you, george? i'm fine. i have a position on l3harris that i put a long time ago when you recommended it, and i've been working on it for sometime. what's your opinion it on it? now >> reporter: i still think it's one of the best companies because it involves basically the technology defense, i don't know why -- they were completely, wrong we were right. you and i got it, right i congratulate you. let's go to alan in california. allen? boo yeah!

>> reporter: beta big guy, what's happening? just keeping the sun on my back. i have spotify, what do you think of spotify? what's your take on? it >> reporter: spotify's a home run. i think the effort that they made two more profitability, just accelerated the trajectory of the. stop your stable on that one, partner. how about andrew in tennessee. andrew! happy new year! booyah from music city. >> reporter: i've got to get there myself, what's going? on yes, what's a special on nashville, when you're gonna do a show? here >> reporter: when my wife says i can go, i guess. or they invite me. if the invite me, i'm going to head there. what's going? on your welcome anytime. i'm a long time holder of pfizer, we've got a huge run. there was a slowdown after its merger with -- a few years ago. you said the bank would write it. out but it's stuck in the 1:20 to 1:30 range for a while, and it seems to be breaking out to new highs. so it do i take profits or keep? holding >> reporter: bank with frank and let it ride. you got it right. we will continue to do that.

with pfizer. oh man, i was just getting in my group. listen, we know the top ten stocks in this market are gonna go through amazing opportunities! but i think if you want to have a well-rounded portfolio, you have to put some health care in that portfolio to. all right, old mad money, i'm gonna bring you interviews from some of the biggest names in health care from jp morgan's health care conference in san francisco, and i just finished up the -- what's it for that company? i'm getting the latest for companies. and the more reason the new ceo of the helm, i'm gonna get a inside look at his priorities in the company. and don't miss my suit up with rows, in the conference. so stick with cramer! ♪ ♪ ♪ don't miss a second on mad money. follow jim on x at @jimcramer. send money to jim, or give us a

call out 1-800-743-cnbc miss something? head to mad money that cnbc.com. cnbc.com. icy hot. ice works fast. ♪♪ heat makes it last. feel the power of contrast therapy. ♪♪ so you can rise from pain. icy hot.

new projects means new project managers. you need to hire. i need indeed. indeed you do. when you sponsor a job, you immediately get your shortlist of quality candidates, whose resumes on indeed match your job criteria. visit indeed.com/hire and get started today. hi, i'm jason and i've lost 202 pounds on golo. so when i first started golo, whose resumes on indeed match your job criteria. i was expecting to lose around 40 pounds and then i just kept losing weight, and moving and moving and moving in a better direction. with golo and release, you're gonna lose the weight.

in order for small businesses to thrive, they need to be smart, efficient, savvy. making the most of every opportunity. that's why comcast business is introducing the small business bonus. for a limited time you can get up to $1000 prepaid card with qualifying internet. yup, $1000. so switch to business internet from the company with the largest fastest reliable network. give your business a head start in 2024 with this great offer. plus, ask how to get up to $1000 prepaid card with qualifying internet. ♪ ♪ ♪

>> reporter: >> reporter: let's -- now that it's done buying horizon therapeutics, if the chairman ceo of m jennifer, a rare tv interview at the -- take a look. what's driving the? stop thanks, jim. i hope bids optimism about the outlook from resin from engine. >> reporter: you do have the fastest-growing portfolio i've seen. and it's and a lot of different causes, a lot of different needs that are on met otherwise. but we're focused on serious unmet medical need and we built the business across four pillars, now we're excited

about the innovation that we have in each of those four pillars. >> reporter: that's go over the one that's most recent that people know about which is horizon, it's a new pillar for you. right, we're excited to have the opportunity to build a rare disease business now. so in addition to the assets that we acquired with horizon, we have a molecule called to have neo switch treats a rare form of escalators very effectively. so we now have a very strong presence and rare disease. based primarily around our decades of expertise and auto immune disorders. so it fits well with whatever otherwise trying to do. >> reporter: you can also have a franchise that many people are talking about the obesity franchise, which had a lot of interesting readouts this year. we rapidly enrolled a phase two trial for the lead product, emeriti. there's a great deal of enthusiasm for that because it looks like it may be differentiated versus the molecules that are a little bit ahead of us in the marketplace. differentiated in terms of dozing schedule, so we're looking at a monthly therapy as

opposed to a therapy that has to be used more often. and at least in the early clinical, they look to be very impressive as to the rate and magnitude of weight loss as well. so i know the market will be excited and we are to. it's better to shoot yourself up twice a year than it is 52, right? for example. >> reporter: i also learn that give something a little further back that could be a pill form. we have about a half dozen other projects, jim, addressing obesity that were excited to generate data for. we think that over time there will be a need for a range of medicines to adjust what we think is a head or a genius problem which is global obesity epidemic. >> reporter: people don't understand, i think, how big you are a cancer franchises. and -- hoping it gets better. but it's likely, maybe they're using one of your drugs. one in five cancer patients in the united states is benefiting from an engine medicine. it reflects our decades of experience and bringing various

medicines to benefit the patients. but at the moment for particularly focused on a new form of medicine, it's called t cell engaging therapy, it's by specific t cell engaging benefits. we have a medicine that's called inside oh that is proving effective for the pm. and other medicine that's attracting attention in -- one call charles limited for small cell lung cancer. and another that is intriguing clinicians which is for -- early clinical studies for prostate cancer. >> reporter: these are big markets, these would be great for therapies. the market has a tremendous medical need in those disease areas. a certainly small cell lung cancer so we've already earned a breakthrough therapy designation there from the fda. we have a breakthrough therapy designation from the inside as well. and a third breakthrough therapy designation at the moment from democrats in combination with their effective fix therapy. >> reporter: a lot of people think we spend too much money

in the country on pharmaceuticals. and people aren't doing doing enough about it. but you have one of the biggest biosimilar portfolio, that's terrific for the country, for the individuals. for what it does for medicare, right? or worldwide a leader in the area of bio simulators. our view is that patients and prescribers, and payers, deserve a choice after the initial property for a molecule has expired. so our objective is to provide a reliable, safe supply of biosimilar medicines. >> reporter: the -- one out of three deaths is because of cardiovascular diseases. you've got a long term, very, i think, thoughtful approach to it that includes right path, that that's an amazing medicine that's hitting its stride. now >> reporter: it's a big drug for big disease. you're right, hard disease is still the leading killer of people in the united states in the world. and one of the reasons it is because they're still far too many people whose ldl career cholesterol, the so called bad cholesterol, it is too high. and the medicine significantly low where is the bad

cholesterol. and so it presents an innovative way to address one of the primary causes in hard attack and stroke. >> reporter: i'd be remiss with the time we have left to not mention that we you've done for. me -- i had 26 migraines a month until i met your drug, this is an incredible innovation. thank you, jim. it is the first drug that was developed specifically for migraine hours and were delighted that you and many migraine are's are innovating -- benefiting from that innovation. >> reporter: i -- some of the other things you do. and repeat, that there's not enough awareness. how do we get more awareness out where the great things you're doing, i want -- i want people to know what you're up to. the good news for society as the innovation in our industry has never been better than it is right now. but the challenge that creates is, there is lots of new therapies for doctors and patients and pairs to be educated about. >> reporter: i think, when i think about the future, i think you have to deal with nvidia to be able to handle --

for gen x, that's gonna be something that's gonna produce something in the next five, ten years and it will be incredible. there's a sea change underway in technology and biology -- >> reporter: a hinge moment! a hinge moment. we're excited to work with nvidia and others to capitalize on ways to use the technology to better descend biology and come up with new therapies for patients who have existing unmet medical needs. >> reporter: and -- then 1985, you did it very well if you bought the stock. we've done pretty well since 1985. >> reporter: a lot of that i think was, you have created an engine that seems to develop something you constantly. and you have many drugs that grow at far higher rates than any other drug i've seen. what engines had since 1985 is a six focus on serious in illness and innovation that addresses the needs of patients suffering from serious illness. it's the secret sauce. there are companies where if they lose this one franchise they're done. but you don't have that.

you have a plethora of drugs so that no one drug was -- if it can go off pathogens it's gonna hurt. you we have a balanced portfolio cross different to therapeutic areas and different geographies. we have 30 something medicines and we aim to generate 30 something billion dollars from the medicines around the world. >> reporter: i never got to congratulate you for joining the dow jones which is a big deal for any company. that's bob brad, with the ceo of m jim. good to talk to. you thank you, jim. great to see. you coming up, investors cringed at a recent dividend slash. so why is this new ceo feel so bullish? >> reporter: you had two -- people were worrying about walgreens. you got off the couch and do this? answers to that and more, next.

♪ ♪ ♪ >> reporter: that's thursday, walgreens supporters saw the

new ceo -- slash the bid by 50% because he thought there are better ways to spend money. is he? right jim spoke with the ceo of walgreens. take a look. tim, why did you take this job? you got a once in a lifetime opportunity, you had to cut the dividend, people were worried about walgreens. you got off the couch to do this? absolutely, jim. i got off the couch and when i got the call, i immediately asked my wife and my daughters, what do you think about me going back to work? but more importantly, back to work to walgreens? and they said, you've gotta take the job. like, there wasn't even a hesitation or a bead which i expected it would be. and it's because this brand, 123 year old company, building trust with consumers, touch points in health care, and importantly, we've all learned how important this company is during the pandemic. when, literally, our lives were given back to us because a vaccine that walgreens and others mobilized to produce an outlet for where we could go

and get back to our lives. so we saw what a great company this was for those touch points, i said, i want to go build off that platform. >> reporter: now, i think people need to know your background, especially -- you did pretty well for people that express groups, didn't you? we did a terrific deal for express crips shareholders, employees, and sick that. because when you look at, we merged with signal, i still stayed for three years, because i believed in, it and it performed, and it continues to perform. we did a good things for our shareholders, we held -- that was compatible, and it's been a terrific merger in the sense. >> reporter: i mentioned it because walgreens had serious ceos that weren't much involved in the health care system. and they were worried about the chewing gum greeting card side, which hasn't attracted a lot of people. you come from health care, can you make your company more of a health care company? there's no question. first, of our more of a health care company today than people actually appreciate. because it's all sort of in the narrative, the question of, we are pivoting to health, care

away from the stores. the answer is actually, if you look at the stores and what's going on, 8 million vaccines this year at the back of the store, already. that's a health care business, right? that's not just putting pills and bottles. that's people touching people. 85,000 of our people touching people every, day 10 million people that lock into our store. so from my perspective, we are in health care today. as i look forward, the place that i am super intrigued to leverage this platform is health services. it's taking those engagement touch points, that we have and the trust that our brand has, the walgreens pharmacist calls and says, hey, your health plan would cover a shot for you, would you like to come in the store to get it? your 45 more times to go in a store to get it rather than if your insurance company tells you to do that. that's one little example of a way that we can leverage the platform and the trust to meaningfully help others that are in the ecosystem achieve their goals. >> reporter: this is classic, we are here to -- i'm talking about the gop on the obesity drugs.

i'm hearing people playing a role, in walgreens. but that's probably wrong, this could be your sweet spot. absolutely, and again that's an example of a product of where we see now, and i'm sure the pharma companies that have innovated those products see, very difficult to keep the patients on those projects over a long period of time. they only work if you stay on them generally speaking. there is additional coaching, side effect management so forth, all of which we are well positioned to help those patients with on behalf of those pharma companies. those drugs are also a great example, though, of how ultimately the reimbursement bottle is gonna have to evolve. because the old reimbursement bottle of letting us all make money on generic spot the brand gets subsidized is no longer going to work. that's a great example, though, we are being paid for services independent from fulfilling the scripts as a key part of how are gonna be reimbursed in the future and create value again for patients, for pharma, for the health plans that are actually paying the bills. all of them aligned around that. >> reporter: you mentioned the pharmacist could play and more important role but you've done everything to fight pharmacists. maybe up to many stores? maybe can get some pharmacists

from ridings as they liquidate stores? there is no question that the store footprint that we have is an important asset, but it's one that we -- as we say, i've been saying, everything is on the table. we know that this year we're closing 200 stores. and that's a good start to making sure we have the right optimized footprint, if we have to walgreens that we can collapse into one based on geography, traffic patterns, and the future of our health care business, then we're gonna look at those kinds of things. but let me also say, we announced that we've started, in march this coming, year this year, we are gonna have the dean's counsel for pharmacy to essentially chart and layout with 17 deans of pharmacy, one from each of our operating areas, a meaningful, iterative, reinvention, evolution of community pharmacy workplace. and our pharmacists are so excited about the fact that we've announced that because what we've said is, listen, we don't think this is the way it's going to be. we've learned with -- we've got to step back, train young pharmacist different, encourage them to come to community pharmacy, we will be the employer of choice for that. >> reporter: let's talk about the stock.

you caught the dividend last, week a lot of people feel, wait a second, maybe your balance sheet is stretched. but you own boots alliances, there's a lot of optionality that. you own village md, maybe could off-load some of that. most importantly, you bought stock! i mean, you wouldn't buy stock -- i know you, you wouldn't buy stock if you thought it was the wrong way to go. listen, i was very happy on friday when i was clear to be able to buy a bunch of stock for i think the announcement went out today. yes, i'm a believer. and we as a company believe. our employees believed. but i think it was important signal, but it was also frankly a smart investment. i was thrilled. i know what the value of this company is going to be in my heart. and i needed to show it with my wallet and i did. >> reporter: i think people need to realize that there are many things you could do, you could either do drug tests, or you could actually be a lap for people. and that's because the iconic -- it still seems to have a lot of

people. how many people go to walgreens every day? somewhere between eight and 10 million every day. every day. >> reporter: who else has that? who sees that many people? who else could help pharma try to get in touch with people? i can't think of anybody who is better positioned than walgreens. >> reporter: hold, on amazon, how many people do they touch every day? they don't touch people directly every day. amazon is amazing for what they've done. >> reporter: yes, they've taken the front store -- but they don't have any 85,000 people touching people every day, building, trust in communities, and i could tell, you that trust is going to be the leverage-able asset that we have as we love to build health services but drive engagement for outcomes for others. >> reporter: and even though people said, wait a second, i -- how did they do it if they cut the dividend. you are saying that it is still an iconic brand. it's still an iconic brand, and it still pays a darn good dividend. we're still at the top of the league table for dividends. our shareholders are still being. paid by michael is that we drive the share price up -- there a lot of people who,

say wait a second, 110 basis points on theft, we should be focused on the fact that when you go to a walgreens people are questioning whether or not you need to pay. i've seen people stealing all the time from the walgreens. >> reporter: yes -- it's unfortunate, and we have stories that are in areas where the cost of keeping the stores open is difficult. and it's something we continue to look at, we work with our industry, we worked with legislators, we're working with their social -- trade association. it's as a leader, because it's a problem we look. at were still in a city where one of the great department stores of our time had to close down. it was an iconic location. so we know what the problem is, but you know what? solving hard problems is how you create shareholder value and this is something we will work our way. through >> reporter: i know you've sailed a lot of problems and made money for people which is why i'm so excited that you are at the head of walgreens. this is the walgreens ceo. congratulations on your new job. thanks, man. >> reporter: good to see. you coming, up to this health care giant in the home run and weight loss? or will a recent acquisition bs

wastes miss? cramer has more, next.

♪ ♪ ♪ >> reporter: jp morgan health care conference i got to sit down with industry's top players. -- tomorrow, morning the company makes his former presentation of the conference. but tonight, you're getting a sneak peek with teresa graham. she's the ceo of russia's formative issue. miss graham, welcome to mad money. thank you very, much it's a pleasure to be here. >> reporter: i've got to tell you, this is a rows that seems to reinvent itself. it's a young company, 20 new medicines in 2015, 50% of sales. you've got to become a nation of great acquisitions, but also tremendous [inaudible]

absolutely, i think if you can say anything about the 125-year history of roaches that we are at the forefront of innovation company. we are consistently looking around the world both internally and externally to find the best innovation that can treat serious diseases that are affecting patients around the world. and that is really what we have been focused on over the last several years. building our own internal pipeline, maximizing our in market portfolio, and making some great acquisitions of partnerships that will continue to expand our footprint in very important areas like the cardiovascular in metabolism caesarean. when let's talk about the karma acquisition. karma therapeutic. so this is one that a lot of people are buzzing about because it's another version of gop dash one, but apparently, you think that's got some very special characteristics. 100%. at the beginning of last, year we really started to look at how did we want to expand our footprints in the cardiovascular metabolism space. and the number one thing that we were looking for was a

company that had a best in class increase, that hopefully had an acid that was ready for the clinic, that maybe had some of their backup essex in its pocket. research platforms, people that were specialized in its field. and all we have to do was look across the baby bridge to berkeley and we found karma. and it's absolutely the perfect example of a company that will allow was, with its best and, class potentially best in class lead asset, really make a difference not only in obesity but really start thinking about where our other disease areas that could potentially play a role. >> reporter: let's stay on, that was so different? before a.d. got eli louis, and -- you inject yourself once a week. is there something better that can be done? absolutely, first, let's talk about the size of this market. about 50% of the world's population, four billion people are likely to be obese by 2025. that is a massive market opportunity, i think.

most analysts pegged the obesity market is somewhere around 100 billion. so for sure there will be many opportunities for many players to be in this market. but i think what's really impressive about carmot, is the lead asset, see three to 88, it has the opportunity to be best in class. the -- potential efficacy profile. this is something we think could change the game for patients who struggled with the b c d. and i think it will have the ability to play significant role in that fight globally. >> reporter: right now you also what maybe a best in class for giant market, which is what age related macular degeneration and diabetic macular d oh which you have a one shot combination that takes care of both. absolutely. so the buys mode, which is our brand that is specific for intervale ian injection, it's established itself as the standard of care globally. it has a superior drying, when you talk to physicians who use

it, their patients really see an improvement in their vision that is incredibly impressive. this is going to be a standard of care therapy and it's when we believe that will be able to take its place globally up there among some of the leading trucks that are out there. >> reporter: now you are doing -- let's talk about artificial intelligence. you did machine learning to develop a new class of antibiotics. we know antibiotics are, basically. we know they basically could stop working, and in some cases they have stopped working. and how has machine learning help develop a new class? machine learning in a.i. is an area that roche jumped into very early in attributed a significant amount of focus. we recently hired a new leader for our genetic research development organization, which is a leader in research machine learning a.i., she's brought with her an incredibly large stuff in this area. really, the opportunity with a eyes to figure out how to

identify new targets faster, test them more quickly, and really figure out how can you increase the predictability and lower the cost and drug development. certainly one area that you could do this in is antimicrobial, is but it really has -- across the spectrum of human disease. >> reporter: how does it work? how does someone just say, look, i think the nvidia graphics cards, whatever, combined with our intelligence and software will work? because it seems a lot of our viewers don't really get what all this artificial intelligence really some changes the game. sure, absolutely. it starts with good old-fashioned biology. we have to have some experiments we run. and when you think of the depth of knowledge and the depth of research that exists -- we have a significant amount of human material to start with. you start test those theories, you put them in the algorithm, the algorithm actually helps you understand will your potential molecule hit the

targets that you wanted to hit, what are the likely side effects. that then spits out a plan for you about how you might conceivably move forward. so when you think about how to do that and what we call a lab in a loop to do so much of what ordinarily would be long cycles of the bench, to be able to do that with a lot more speed, and a lot more predictability, it can quite easily revolutionize the way that we identify targets and drugs. >> reporter: that makes sense to, me it makes sense. i don't understand it. one last, thing i do want to be -- i'm remiss if you'd i didn't mention your incredible franchise -- is still the best in class. absolutely, i think when you look at what jean tech and russia have done for our college -- over the last 20 years it's been revolutionary. you can essentially train many types of cancer to chronic diseases but i think some of the data that we've just

released for the brand new molecule, for home -- breast cancer really has the opportunity again to be transformative, and -- for breast cancer which is 80% of the women who have breast cancer has the opportunity to be a new foundational backbone and much more tolerable, much more efficacious drug. we have new products that are happening, new products that are happening in solid tumor the continued level of innovation is extremely high. over the course of the next 18 to 24 months are gonna see a lot of data coming out of roche that i hope is going to continue to reinvent wet hair looks like. >> reporter: you run amazing pharmaceutical business. and i have to thank you for everything you do for saving so many lives. great to talk to you. thanks, jim. appreciate it. ♪ ♪ ♪ ♪ ♪ ♪

♪♪ ♪♪ ♪♪ ♪♪ ♪♪ i think i'm ready for this. heck, yeah! with e*trade you're ready for anything. marriage. kids. college. kids moving back in after college. (applause) finally, we can eat. ♪ you know you make me wanna... ♪ and then we looked around and said, "wait a minute, this isn't even our stroller!" (laughter)

you live with your parents, but you own a house in the metaverse? mm-hmm. cool! i don't get it. here's to getting financially ready for anything. and here's to being single and ready to mingle. who's ready to cha-cha? ( ♪♪ ) the first time you made a sale online with godaddy

was also the first time you heard of a town named dinosaur, colorado. we just got an order from dinosaur, colorado. start an easy to build, powerful website for free with a partner that always puts you first. start for free at godaddy.com ♪ (upbeat music) ♪ ( ♪♪ ) constant contact's advanced automation lets you send the right message at the right time, every time. ( ♪♪ ) constant contact. helping the small stand tall. ♪ ♪ ♪

>> reporter: it is time for a lightning round, where we call take calls -- [inaudible] play the sound! and then the lightning round is over. are you -- [inaudible] bob. bouchard, jim. thanks for taking my call. >> reporter: my pleasure, what's shaking? thank you.

i started accumulating stock in this company about two weeks ago, it's a brazilian company, it's the largest digital bank in the world, it's a morgan stanley top pick and lauren bar buffet for berkshire half -- when they first went public. i would like your opinion, what's your opinion on new holdings? >> reporter: i never thought i'd say this but it's a brazilian stop but i absolutely like. we have a winner, it's fire. let's go to nick and florida. nick! booyah jimmy de, happy new year. >> reporter: same to you, partner. what's going? on i like your stock, new york, new york thinking conceptually. what might work in the -- put holdover some that's an bolts for things in a building project and i started thinking, is that all that home improvement spending baked in right now? or are the real nuts and bolts them if the economy in reality

the credit cards that pay for everything? so jim, my stock question tonight instead, is the personal spending favorite, visa. >> reporter: i don't, know because rachel's father, i think we ought to be thinking of buying home depot and then secondarily visa, but i like you're thinking. i like your conceptual analysis of these. a good stop. mark in wisconsin. mark? dr. cramer, happy new year and thank you for taking my call. >> reporter: radio, professor. what's happening? all right, semiconductors stop, developing, cutting edge, technology. i think the technology will make it but the company, i'm beginning to wonder, bob. i noticed a lot of insiders selling. so, what should i do with an v t s naivete stop? >> reporter: they've gotta make money. let's just say exit now the

toss. let's go to mark in michigan. mark? hey, jim. thanks for taking my call. >> reporter: of course. i'm a new member also. >> reporter: thank you. i had had a stop in my portfolio for a while, sticker cyp k. and recently it is skyrocketing and share price. should i write a little longer? >> reporter: you know right, i'm not so sure that -- a lot of people think that vargas is gonna buy them, the stock is not very big. that's half -- cell have tomorrow, and then let the rest run. i i'm going to roberts in california, robert. hey, jim, booyah, how are you doing? >> reporter: how are you? i'm in traffic. i want to ask you about what's stock -- compared to another stop. we have right platforms and marathon digital. >> reporter: but are we doing with these? let's not fooling around. you want bitcoin by bitcoin.

i think bitcoin is topping out by the way. i think enough is enough, and cushing is coaching. and that lay these and gentleman is the conclusion of the lightning round! the lightning round is sponsored by charles schwab. coming up, bristol myers is on a shopping spree. can the pipeline growth powered their future? we are writing the next chapter of this company. we have a lot of real work here. >> reporter: stick with cramer. >> reporter: stick with cramer. ng traders even more ways to sharpen their skills with tailored education. get an expanding library filled with new online videos, webcasts, articles, courses, and more - all crafted just for traders. and with guided learning paths stacked with content curated to fit your unique goals, you can spend less time searching and more time learning. trade brilliantly with schwab. (clock ringing) go. and go and go and go.

(tense music) but what if you. (tense music) stop! you work hard. it's time for a bank that'll work hard for you. everbank performance savings is built to put your money to work with some of the highest rates in the country. going, that's what got you where you want to be. we're the partners for your next move. everbank. advantage, you. ♪ ♪ ♪

>> reporter: nearly every big pharma company has a problem. the biggest drugs are on the losing penn protection. but one of them seems to have a solution. bristol myers had announced -- in the last quarter of 2023. with the? plan we spoke to chris burners, the ceo of the company, and at the jpmorgan's conference. chris, you just went on the huge shopping spree. it's basically given us a new bristol myers. what is a look? like jim, first of all it's good to be here with you. it's an exciting time to be taking over bristol-myers squibb. we are writing the next chapter for this company. we have an incredible pipeline of recently launched or launching patents. i don't think our pipeline has

been richer than it's ever been and we have real financial strength that will allow us to go and bring innovation into the company from the outside and that's what we've done for the most recent deals. we had a company called karoun oil, and it was dazzling. i'm talking about the first antipsychotics in six years, and the other ones don't work. this is going to be a great thing for bristol. tell us about it. karoun as an incredibly exciting asset for us. we have been building and early stage pipeline of newer degenerative diseases, and this potential acquisition gives us the ability to accelerate -- as you point out, there has been much in the way of innovation here for 30 years. car x d has the potential to be transformative in terms of efficacy, the safety looks very good, initially as a motto therapy, but ten chalet in combination. -- alzheimer's disease psychosis, and alzheimer's disease

agitation. the so where excited about this acquisition. >> reporter: people have tried to work on schizophrenia for bipolar, and a lot of people feel it's impossible. why are you so optimistic? it is a unique mechanism of action. here it targets and one and m four. that's really unique and what that gives us the ability to do is develop really good efficacy without the side effects that we see with the atypical's. and the setbacks have been a great limit. are we see the potential, initially with schizophrenia, and adjunct of schizophrenia, with his conjunction with doubles. this is great opportunities for patients. we believe commercially they're very attractive opportunities. and as i said, the real potential is not just a neuroscience. it's the branch to neuro day generation. you know, we are on the potential upset wing of really making meaningful improvements in the lives of patients. with alzheimer's disease, and we are excited to bring this in. >> reporter: a giant market. you mentioned side facts, when

and -- they get cured and go off. it that has been this twin problems. will it be solved by corona? we have multiple studies with colleagues that showed profound efficacy and a safety profile that doesn't include some of those things that really, as you point out, have been greatly meters for the existing therapy. >> reporter: other acquisitions that have been a very exciting, rising bio, that makes a lot of sense. these again were reinvented by bristol. if you see where we're playing today as a company, we have depth in oncology and cardiovascular diseases. as we look at the acquisitions you just highlighted, they give us an extra definition on oncology. they are -- if you look at murati, it gives us a nice entrée into targeted therapies, and with a grazed bio, we are getting an acquisition that gives us the potential to bring in radiopharmaceuticals which is one of the fastest-growing

platforms and all of solid tumor on college, e we love the technology from this company and look for to completing that acquisition as well. >> reporter: these are longer range -- but people are gonna, say wait a second, you're talking about something that could be gigantic in 20, 27, is the dividend safe and could we bridge a till we get there? listen, we're willing to continue to do a few things really well. we have one word, grow the assets we have, today and we will double or on the pipeline, and -- that includes a commitment to that dividend which we've been increasing for 15 consecutive years. >> reporter: that's very important because i regard you as -- a dividend aristocrat. i would hate to see anything not go right there. let's talk about the existing drugs. you bought cell gene, a lot people feel, what did a do for you? but it generate a lot a cash. it generated a lot of cash in and gave us an exciting pipeline. we have a number of important drugs from that acquisition and

one other thing, jim, we're not only focused on bringing really exciting individual assets, we are focused on platforms. and at the sultriness acquisition gave us two exciting acquisitions, self therapy, we've established a position in hematology. we are going to take that technology and treat auto immune diseases. proteins aggregation, the first generation of salmons have transformed multiple milam la. we are gonna take that. no we see exciting -- the new bristol, as you just described, is not just about individual assets, it's a looking at platforms that could treat and hopefully provide meaningful improvement to the patients lives across indications and that's what we've got. >> reporter: let's talk about cardiovascular, people who watch nfl have seen -- you see something right, now, tangible to give it to be people when there was nothing. that's another business development, the broad in kansas city as, we're super excited about that asset. we are getting credible feedback from patients, from

physicians that launched it to a great start, as i talked about it in my presentation today. that's got significant potential going forward, we are heavily investing in that. >> reporter: one last question, this is bristol myers. this is a bedrock company. you've been on a lot of companies. when you compare, than what could happen for the next four, five years of your tenure? what i love about bristol myers's quipped are three things. first of all, we have great science at this. this is transforming it's a real patient benefit. second, we have an exciting, young portfolio. we have a number of l o, east but if you look at this portfolio and the growth potential, yes, absolutely. we have great potential. and finally, the people at this company are exceptional. i have the privilege of working with some of the brightest, most dedicated hardworking employees. this comes as a great history and we're gonna be focused on improving the growth profile of the company and exiting this decade as one of the strongest growth companies of the industry. >> reporter: this is a great thing to, hear chris burners

the ceo of bristol-myers squibb. great to see. you have to be. here >> reporter: i learned so much today from the ceos who joined us on the show, and don't miss our actual pack line of tomorrow on day to have the jpmorgan health care conference. i want to always say those markets elsewhere, and i always want to find it for you right here on mad money. i'm jim right now on last call, boeing 737 max debacle. taking another turn with another airline. we have the breaking developments, speaking of breaking news, hewlett-packard nearing a deal with juniper networks. the reporter who broke the story is here. oil rolling, again, a surprise move by saudi arabia can be great news for what you pay at the pump. elon musk firing back. does a stunning report about his drug use even matter to investors? time for earnings and there is